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Abstract
Background: There is only one established drug binding site on sodium channels. However, drug binding of sodium
channels shows extreme promiscuity: ,25% of investigated drugs have been found to potently inhibit sodium channels.
The structural diversity of these molecules suggests that they may not share the binding site, and/or the mode of action.
Our goal was to attempt classification of sodium channel inhibitors by measuring multiple properties of inhibition in
electrophysiology experiments. We also aimed to investigate if different properties of inhibition correlate with specific
chemical properties of the compounds.
Methodology/Principal Findings: A comparative electrophysiological study of 35 compounds, including classic sodium
channel inhibitors (anticonvulsants, antiarrhythmics and local anesthetics), as well as antidepressants, antipsychotics and
neuroprotective agents, was carried out using rNav1.2 expressing HEK-293 cells and the QPatch automatic patch-clamp
instrument. In the multi-dimensional space defined by the eight properties of inhibition (resting and inactivated affinity,
potency, reversibility, time constants of onset and offset, use-dependence and state-dependence), at least three distinct
types of inhibition could be identified; these probably reflect distinct modes of action. The compounds were clustered
similarly in the multi-dimensional space defined by relevant chemical properties, including measures of lipophilicity,
aromaticity, molecular size, polarity and electric charge. Drugs of the same therapeutic indication typically belonged to the
same type. We identified chemical properties, which were important in determining specific properties of inhibition. State-
dependence correlated with lipophilicity, the ratio of the neutral form of molecules, and aromaticity: We noticed that the
highly state dependent inhibitors had at least two aromatic rings, logP.4.0, and pKa,8.0.
Conclusions/Significance: The correlations of inhibition properties both with chemical properties and therapeutic profiles
would not have been evident through the sole determination of IC50; therefore, recording multiple properties of inhibition
may allow improved prediction of therapeutic usefulness.
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Introduction
Pharmacological modulation of sodium channels by sodium
channel inhibitors (SCIs) is crucial in local anesthesia, in the
treatment of certain types of epilepsy and cardiac arrhythmia (we
will refer to these drugs: local anesthetics, anticonvulsants and class
I antiarrhythmics, as classic SCIs). Several SCI drugs are also used
for the treatment of neuropathic pain, muscle spasms, Alzheimer’s
disease, amyotrophic lateral sclerosis and as mood stabilizers [1],
although in some of these indications the role of sodium channel
inhibition is unsettled. Furthermore, SCIs are intensively studied
(preclinical/clinical phase) for a number of other indications
including various pain syndromes, stroke/ischemia, neurodegen-
erative diseases (Parkinson’s disease, multiple sclerosis), and
psychiatric disorders [1,2]. The basis of the therapeutic versatility
of SCIs is poorly understood. Isoform selectivity, which would be
the most plausible explanation, is minimal for most SCIs [3].
Instead, it is conceivable that different therapeutic profiles are
caused by different mechanisms of action, such as different binding
sites, different access pathways to the binding site [4] and different
state-selectivity [5]. Current knowledge regarding the relationship
between chemical properties of SCIs, biophysical properties of
inhibition (reflecting mechanism of action) and therapeutic profile
is limited.
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15568There are several different toxin binding sites on sodium
channels [6,7], but only one established drug binding site.
Therefore, it was puzzling to learn that according to a recent
study, about 25% of clinically used drugs were sodium channel
inhibitors [8]. The criteria for being classified as a sodium
channel inhibitor in that study was to cause at least 60%
inhibition at 10 mM concentration; notably, classic SCIs such as
lidocaine or lamotrigine failed to fulfill this criteria. A ‘‘local
anesthetic receptor’’, which can host every fourth drug with an
affinity higher than that of lidocaine, is at least curious.
Furthermore, the identity of residues involved in drug binding
seems to vary from drug to drug [9]. Even the contribution of the
best established component of the binding site, Phe1764 (rNav1.2
numbering), was found to be minimal in 8 out of the 28 SCI
compounds studied thus far [9]. The overall picture suggests
multiple overlapping binding sites within the inner vestibule, and
for certain drugs completely different binding sites. Furthermore,
we also know that binding sites at different conformations of the
channel are fundamentally different, and most probably impose
different orientations and positions on bound drugs [10,11,12].
We assumed that binding to different binding sites (either within
the supposed overlapping multi-binding site of the inner
vestibule, or out-of-inner-vestibule binding sites), or preferring
different conformation of the binding site should be reflected in
the experimentally measurable properties of inhibition. We aimed
to measure properties of inhibition in order to obtain indirect
information regarding possible binding sites and/or modes of
action. For this purpose, it is essential to acquire more
information than simply determining the concentration-response
relationship.
The way the acquisition of multiple biophysical properties was
carried out was unlike conventional analyses of the mode of action.
These require multiple protocols, where the exact parameters of
protocols must be adjusted individually to specific drugs.
Furthermore, exploration of the mode of action of a drug is
always an iterative process: responses to initial protocols are used
to design new protocols, and to adjust parameters of the protocols
to individual drugs. This of course compromises comparability of
data with different drugs. Our aim is to develop an approach
which can be adopted by pharmaceutical companies, therefore we
confined ourselves to protocols which require no more cost or time
than a single measurement of inhibition, but which can give
radically more information regarding the mode of action of the
drug. We used two very simple protocols, which can even be
applied within the same experiment, the whole process of ‘control
measurement’ – ‘measurement of drug effect’ – ‘measurement
after washout’ requires no more than 10 minutes (it is limited by
the onset rate of slowly acting drugs). However, we took care to
extract all possible useful information from this measurement.
From the first protocol, where 5 Hz trains of depolarizations
were applied, we extracted potency, reversibility, time constants of
onset and offset and use-dependence. Affinity to hyperpolarized
state (commonly termed ‘‘resting state affinity’’; Kr), affinity to
depolarized states (commonly termed ‘‘inactivated state affinity’’;
Ki), and state dependence (calculated from the ratio of Kr and Ki)
were extracted from ‘‘steady-state’’ availability curves (for details
of the protocol, see Materials and Methods).
We investigated 44 compounds of different chemical structures
and different therapeutic classes (Table 1). Twelve of the
compounds (nisoxetine, mirtazapine, bupropion, nefazodone,
nialamide, moclobemide, chlorprothixene, clozapine, tiapride,
ritanserin, mecamylamine, deprenyl), to the best of our knowledge,
have not been tested before for SCI activity. Most drugs were
acting on the CNS, we placed special emphasis on antidepressants,
which, intriguingly, were found to be the therapeutic group with
the highest incidence (72%) of SCI activity in the above quoted
study of ,400 drugs [8]. Nine of the 44 compounds did not
produce effective inhibition even at the highest concentrations
used. For the remaining 35 drugs, the comparative electrophys-
iological investigation was completed. Recording multiple bio-
physical properties for these drugs made it possible to delineate
distinct groups in the multi-dimensional ‘‘biophysical space’’
(defined by biophysical properties of inhibition; in analogy to the
‘‘chemical space’’ defined by chemical descriptors [13]), which
correspond to distinct types of inhibition. The identified types
correlated significantly with therapeutic categories.
Next, we aimed to investigate how specific locations in the
‘‘biophysical space’’ correspond to specific chemical properties,
i.e., locations in ‘‘chemical space’’.
Some potentially useful general principles have already been
discovered. Lipophilicity, pKa (acidic dissociation constant), and
the size of the molecule were proposed to be the most important
predictors of properties of inhibition [14].
Lipophilicity can be quantified by either logP, which is the
logarithm of the octanol-water partition coefficient of the neutral
form of the molecule, or logD (logarithm of the distribution
coefficient), which measures the distribution of all forms that are
present at a certain pH value. Because the pKa of the studied SCIs
are typically between 7.0 and 10.7, most drugs are predominantly
positively charged at neutral pH, and lose their charge at higher
pH values. For this reason, logD is increasing with higher pH,
approaching logP as an upper limit. A linear correlation was found
between logP and the logarithm of IC50 values [14,15,16,17,18].
Because local anesthetics are predominantly charged, basic
compounds, a pKa value between 7.5 and 10 was considered a
requirement for being an effective SCI. However, SCI anticon-
vulsants are predominantly neutral, and several very potent
neutral SCIs has been discovered recently [19]. In a recent
comparative analysis of 139 compounds from 73 publications we
found no correlation between pKa and potency [19]. The pKa
value nevertheless is a major determinant of which access
pathways to the binding site are passable for the drug, and thus
has been shown to affect onset/offset kinetics and use-dependence
[4,20,21].
Molecular weight has been shown to correlate with potency
[17], and with the kinetics of inhibition [22,23]. More exactly it
was not molecular weight that best predicted recovery kinetics, but
the width of the molecule at the aromatic end [24].
Most of these results were based on studies of a single chemical
and therapeutic class of SCIs. In this current study we attempted
to detect similar general principles for a larger, more diverse group
of SCIs. Our specific questions were the following:
N Which measure of lipophilicity, logP or logD better predicts
potency?
N Are there chemical descriptors which specifically predict
individual biophysical properties of inhibition? Most impor-
tantly, can we find some difference between descriptors which
determine Kr and with Ki? If yes, then we can deduce
something regarding the chemical interactions of the drug with
resting and inactivated conformations of the channel. High
state-dependence is considered to be essential for good
therapeutical applicability. Which chemical properties predict
high state-dependence?
N Which chemical properties determine specific types of
inhibition (i.e., can we predict the type of inhibition from the
chemical structure)?
Classification of Sodium Channel Inhibitors
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channel inhibitor.
Drug Code Main use Mechanism of action plasma conc.
mg/ml mM
Fluoxetine FLX antidepressant SSRI
a 0.38 [44] 1.099
Sertraline SRT antidepressant SSRI
a 0.14 [44] 0.409
Paroxetine PRX antidepressant SSRI
a 0.38 [44] 0.22
Amitriptyline AMI antidepressant TCA
b 0.064 [44] 0.204
Imipramine IMI antidepressant TCA
b 0.2 [44] 0.631
Desipramine DMI antidepressant TCA
b 0.1 [44] 0.330
Maprotiline MPR antidepressant NRI
c 0.25 [45] 0.797
Nisoxetine NIS antidepressant NRI
c 0.05 [46] 0.159
Mianserin MIA antidepressant NaSSA
d 0.01 [47] 0.037
Mirtazapine MRZ antidepressant NaSSA
d 0.04 [44] 0.158
Bupropion BPR antidepressant NDRI
e (Augmenter) 0.14 [44] 0.514
Venlafaxine VFX antidepressant SNRI
f 0.17 [44] 0.532
Nefazodone NFZ antidepressant SNRI
f (Augmenter) 1.52 [48] 3.007
Trazodone TRZ antidepressant (Augmenter) 1.5 [44] 3.673
Nialamide NIA antidepressant non-sel.MAO
g inh. NDA NDA
Moclobemide MCL antidepressant MAO
g -A inhib. 0.29 [49] 1.484
Haloperidol HAL antipsychotic D2 antagonist 0.02 [44] 0.053
Chlorpromazine CPM antipsychotic D2 antagonist 0.1 [44] 0.281
Chlorprothixene CHX antipsychotic D2 antagonist 0.07 [50] 0.200
Clozapine CLZ antipsychotic D4 antagonist 0.55 [44] 1.671
Tiapride TIA antipsychotic D2 antagonist 0.56 [51] 1.535
Carbamazepine CBZ antiepileptic SCI
h 9.3 [44] 39.362
Lamotrigine LTG antiepileptic SCI
h 2.5 [44] 9.762
Phenytoin DPH antiepileptic, 1b antiarrhythmic SCI
h 10 [44] 39.64
Topiramate TOP antiepileptic SCI
h 5.5 [44] 16.21
Zonisamide ZON antiepileptic SCI
h 28.4 [44] 133.82
Gabapentin GAB antiepileptic Ca
2+-ch. inhib. 4 [44] 23.359
Bupivacaine BPV local anesthetic SCI
h 0.8 [44] 2.462
Lidocaine LID local anesthetic, 1b antiarrhythmic SCI
h 3.5 [44] 12.925
Mexiletine MEX 1b antiarrhythmic SCI
h 2 [44] 9.271
Flecainide FLC 1c antiarrhythmic SCI
h 0.46 [44] 0.965
Procainamide PRC 1a antiarrhythmic SCI
h 2.5 [44] 9.198
Ranolazine RAN antianginal SCI
h 3.59 [52] 7.173
Memantine MEM Alzheimer’s - dis. NMDA antagonist 0.02 [53] 0.075
Riluzole RIL Amyotrophic lateral sclerosis SCI
h, glutamate release inhibitor 0.17 [44] 0.739
Diclofenac DIC NSAID
i COX
J inhibitor 2 [44] 6.287
Ritanserin RIT anxiolytic 5HT2A-C antag. 0.14 [54] 0.299
Ambroxol AMB analgesic, mucolytic SCI
h 0.15 [55] 0.362
Silperisone SIL muscle relaxant SCI
h 0.45 [56] 1.484
Tolperisone TOL muscle relaxant SCI
h 0.43 [57] 1.508
Flunarizine FLR migraine Ca
2+-ch. inhib. 0.06 [58] 0.113
Lifarizine LIF neuroprotective SCI
h,C a
2+-ch. inh. 0.02 [59] 0.046
Mecamylamine MEC smoking cessation nACh antagonist 0.02 [60] 0.118
Deprenyl DPR Parkinson’s – dis. MAO
g -B inhib. 0.001[44] 0.005
Abbr.:
aselective serotonin reuptake inhibitor,
btricyclic antidepressant,
cnorepinephrine reuptake inhibitor,
dnoradrenergic and specific serotonergic antidepressant,
enorepinephrine-dopamine reuptake inhibitor,
fserotonin-norepinephrine reuptake inhibitor,
gmonoamino-oxidase,
Classification of Sodium Channel Inhibitors
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e15568We succeeded to identify chemical descriptors which determine
different types of inhibition, and which predict specific biophysical
properties of inhibition (Kr,K i,I C 50, state-dependence, revers-
ibility, use-dependence, onset and offset time constants). We
observed that different chemical properties determine low Kr (high
pKa and logP), and low Ki (high logP, logD and aromaticity).
State-dependence, therefore can be predicted by calculating these
chemical descriptors of molecules.
Results
Assessment of properties of inhibition
Properties of drugs were tested using two simple protocols.
The dynamics of the onset and offset of inhibition was
monitored using 5 Hz trains of five depolarizing pulses from a
holding potential of 290 mV to 210 mV. The trains were
repeated every 20 s. Drugs were applied after 10 control trains and
10 trains were delivered in the presence of the drug. The drug was
then washed out, and the 10 trains were repeated. Each drug was
applied at a single concentration, which was chosen to cause 25%
to 75% inhibition (pilot experiments established appropriate
concentrations). Of the 44 investigated drugs nine either caused
less than 10% inhibition even at the highest concentration used
(mecamylamine, tiapride, topiramate, zonisamide, procainamide,
gabapentin, moclobemid, nialamide), or their IC50 were exceed-
ingly high compared to their plasma concentration (mecamyl-
amine, deprenyl). Therefore these were excluded from analysis of
further properties of inhibition (marked ‘‘dropout’’ in Table 2).
We measured inhibition (Inh; from which we calculated IC50
values as described in Materials and Methods), reversibility of
inhibition (Rev) and use-dependence (UD), as well as time constant
of onset (ton) and offset (toff). The calculation of IC50,
quantification of Rev and UD, and the determination of time
constants are illustrated in Figure 1A. Because ton should be
concentration-dependent if we assume a single binding reaction,
we excluded it from the analyses. Reversibility measured by the
QPatch instrument did not match reversibility values obtained by
classic patch clamp (data not shown). It has been observed that
washout of lipophilic compounds is delayed in automated
electrophysiology platforms (e.g. [25]). However, reversibility even
under these experimental conditions is a useful source of
information regarding the physicochemical properties of drugs.
Comments on the interpretation of these properties (Rev, ton and
UD) are in Results S1.
Standard steady-state inactivation protocols were used to
measure the shift of steady-state availability curve caused by the
drugs. Currents were evoked by a 10 ms test pulse to 210 mV,
preceded by 400 ms pre-pulses from 2150 to 230 mV. The
holding potential was 2120 mV. Because the inhibition at
hyperpolarized potentials (Inh2150), and the shift of the availability
curves (DV1/2) are both concentration-dependent properties, we
calculated affinities to hyperpolarized and depolarized states
(‘‘resting state affinity’’: Kr, and ‘‘inactivated state affinity’’: Ki),
which, on the other hand, are concentration-independent
characteristics of individual drugs. Calculation of Kr and Ki
values are described in Materials and Methods, and illustrated in
Figure 1E. State-dependence (SD) was quantified as the ratio Kr/
Ki. Values of the eight properties for individual drugs are shown in
Table 2 and Table 3. The calculated Kr and Ki values can be
compared to data from the literature in Table 3.
Classification of drugs based on properties of inhibition
At least three distinct types of inhibition were identified by
observing drug behavior during the 5 Hz train and the steady-
state inactivation protocols, and the examples are shown in
Figure 1A–D.
‘Type 1’ (Figure 1A) drugs had high potency (Ki 0.73 to 6.1 mM;
IC50 14 to 43 mM), slow onset and offset kinetics (time constants
between 10 and 53 s), partial reversibility (between 0.2 and 0.6)
and use-dependence (1.09 to 1.66). Drugs belonging to this type
were mostly antidepressants: fluoxetine, sertraline, paroxetine,
amitriptyline, imipramine, desipramine and maprotiline, as well as
the antipsychotic haloperidol, and the anxiolytic ritanserin.
The properties of ‘Type 2’ drugs (Figure 1B and C) were low
potency (Ki 17 to 88 mM; IC50 .95 mM), fast kinetics (time
constants ,27 s) and almost full reversibility (.0.75) Drugs
belonging to this type were the three effective anticonvulsants
(carbamazepine, lamotrigine, phenytoin), the Class IB antiar-
rhythmic lidocaine and mexiletine, as well as diclofenac,
venlafaxine, tolperisone, bupropion, ambroxol and memantine.
The group can be further divided: lidocaine, mexiletine, ambroxol
and tolperisone (Figure 1B) were use-dependent (UD 1.14 to 1.39).
Anticonvulsants, memantine, venlafaxine, bupropion and diclofe-
nac (Figure 1C), on the other hand, showed no significant use-
dependence (0.95 to 1.05).
A distinct group, ‘Type 3’, was formed by the neuroprotectants
flunarizine and lifarizine (Figure 1D). These drugs had high
potency, very slow kinetics, apparent irreversibility (no recovery
within the 200 s of washout within this experimental environment)
and no use-dependence.
Of the remaining 13 drugs 7 were between ‘Type 1’ and ‘Type
2’ (nisoxetine, clozapine, silperisone, mianserine, mirtazapine,
ranolazine and trazodone; named ‘Type 4’), 2 compounds
between ‘Type 1’ and ‘Type 3’ (the antipsychotics chlorpromazine
and chlorprothixene), while the remaining 4 drugs, bupivacaine,
flecainide, nefazodone and riluzole seemed to have their own
specific type of inhibition: Bupivacaine with high use-dependence
and state-dependence; flecainide, with high use-depencence but
low state-dependence and low Kr, indicating that it is an open
channel blocker; nefazodone with an exceptionally high state-
dependence, and riluzole with high state-dependence and no use-
dependence.
Figure 2A illustrates quasi-three dimensional projections of drug
locations in the eight-dimensional ‘‘biophysical space’’. Rev values
are plotted against Kr and Ki values (left and right panel,
respectively), while the color indicates toff. Non-use-dependent
drugs are marked by underlined italic fonts. The types defined
above are circled. Note how the relative position of drugs with a
high SD changes: Flunarizine (FLR), chlorpromazine (CPM),
chlorprothixene (CHX), riluzole (RIL), bupivacaine (BPV) and,
most of all, nefazodone (NFZ) all move to the left on the Rev vs. Ki
plot as compared to the Rev vs. Kr plot.
hsodium channel inhibitor,
inon-steroidal anti-inflammatory drug,
jcyclooxigenase-inhibitor.
doi:10.1371/journal.pone.0015568.t001
Table 1. Cont.
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Drug cc
a nI n h b ± SEM IC50 Rev c ± SEM UD d ± SEM ton ± SEM toff ± SEM
code mM mMs s
ANTIDEPRESSANTS
FLX 30 5 0.41 ± 0.08 43.09 0.33 ± 0.09 1.14 ± 0.01 53.38 ± 4.86 39.34 ± 12.4
SRT 30 7 0.68 ± 0.07 14.31 0.23 ± 0.02 1.42 ± 0.03 26.55 ± 7.93 29.55 ± 10.5
PRX 30 6 0.65 ± 0.06 16.23 0.34 ± 0.08 1.46 ± 0.04 32.07 ± 5.25 35.99 ± 5.86
AMI 30 7 0.56 ± 0.07 23.46 0.50 ± 0.09 1.66 ± 0.05 10.54 ± 1.42 16.95 ± 3.84
IMI 30 5 0.61 ± 0.04 19.46 0.43 ± 0.05 1.51 ± 0.05 16.97 ± 2.24 16.03 ± 2.26
DMI 30 5 0.62 ± 0.03 18.28 0.43 ± 0.06 1.32 ± 0.06 32.02 ± 3.93 51.82 ± 4.99
MPR 10 5 0.30 ± 0.04 23.03 0.34 ± 0.07 1.17 ± 0.04 22.07 ± 2.39 25.21 ± 1.1
NIS 100 6 0.57 ± 0.06 75.72 0.66 ± 0.05 1.33 ± 0.04 20.71 ± 2.25 23.41 ± 3
MIA 30 5 0.41 ± 0.06 42.77 0.7 ± 0.13 1.25 ± 0.04 17.78 ± 3.35 16.98 ± 3.35
MRZ 100 7 0.43 ± 0.08 132.28 0.89 ± 0.03 1.14 ± 0.01 3.99 ± 0.01 7.47 ± 1.05
BPR 100 4 0.15 ± 0.04 565.02 0.92 ± 0.03 1.04 ± 0.02 4.6 ± 1.16 12.45 ± 2.77
VFX 100 4 0.12 ± 0.02 726.99 0.89 ± 0.06 1.05 ± 0.01 4.85 ± 2.04 5.2 ± 1.63
NFZ 30 4 0.39 ± 0.09 46.43 0.51 ± 0.09 1.22 ± 0.04 8.75 ± 0.57 10.93 ± 0.63
TRZ 100 5 0.16 ± 0.04 365.11 0.67 ± 0.10 1.02 ± 0.01 8.25 ± 2.42 16.64 ± 3.02
ANTIPSYCHOTICS
HAL 30 4 0.59 ± 0.09 20.44 0.59 ± 0.02 1.56 ± 0.07 11.91 ± 2.75 24.11 ± 5.9
CPM 30 4 0.41 ± 0.08 47.28 0.07 ± 0.03 1.30 ± 0.06 14.81 ± 2.44 9.67 ± 2.18
CHX 30 4 0.28 ± 0.05 42.54 0.18 ± 0.05 1.25 ± 0.07 7.24 ± 3.85 14.41 ± 1.11
CLZ 100 5 0.51 ± 0.03 94.54 0.63 ± 0.02 1.31 ± 0.02 10.38 ± 0.51 16.4 ± 2.71
ANTICONVULSANTS
CBZ 300 5 0.29 ± 0.02 718 0.87 ± 0.05 0.98 ± 0.02 3 ± - 10.01 ± 2.33
LTG 300 4 0.25 ± 0.03 904.86 0.85 ± 0.09 0.97 ± 0.01 8.19 ± 1.23 18.1 ± 1.32
DPH 300 6 0.18 ± 0.03 1392.4 0.75 ± 0.07 1.01 ± 0.01 5.20 ± 1.20 15.96 ± 3.86
LOCALANESTHETICS/ANTIARRHYTHMICS
BPV 100 4 0.60 ± 0.04 67.72 0.75 ± 0.05 1.62 ± 0.05 7.95 ± 0.05 16.73 ± 1.43
LID 300 6 0.23 ± 0.02 1084.4 0.95 ± 0.06 1.14 ± 0.03 3 ± -6 ± 0.31
MEX 300 4 0.57 ± 0.04 230.54 0.78 ± 0.04 1.39 ± 0.03 8.6 ± 0.87 12.93 ± 0.72
FLC 300 4 0.82 ± 0.03 67.63 0.57 ± 0.04 1.34 ± 0.02 20.04 ± 1.26 64.97 ± 5.51
MISCELLANEOUS
RAN 100 4 0.16 ± 0.04 354.55 0.89 ± 0.07 1.21 ± 0.02 8.13 ± 1.75 13.24 ± 1.98
MEM 100 5 0.32 ± 0.02 230.49 0.93 ± 0.05 0.99 ± 0.03 3.51 ± 0.22 8.98 ± 1.61
RIL 30 4 0.27 ± 0.07 80.98 0.52 ± 0.08 0.95 ± 0.03 3.9 ± 0.07 17.6 ± 5.42
DIC 100 6 0.56 ± 0.1 561.19 0.95 ± 0.04 1.01 ± 0.04 7.19 ± 1.89 26.43 ± 5.31
RIT 30 5 0.15 ± 0.06 23.62 0.37 ± 0.02 1.09 ± 0.00 14.38 ± 2.64 22.28 ± 6.47
AMB 100 5 0.51 ± 0.1 95.94 0.81 ± 0.06 1.24 ± 0.02 5.74 ± 1.14 6.78 ± 1.1
SIL 100 6 0.45 ± 0.06 120.65 0.8 ± 0.04 1.16 ± 0.02 4.1 ± 0.56 15.21 ± 4.12
TOL 100 5 0.23 ± 0.01 335.95 0.95 ± 0.03 1.14 ± 0.04 5.57 ± 1.57 7.42 ± 1.47
FLR 100 4 0.85 ± 0.04 17.65 0.004 ± 0.001 1.06 ± 0.03 132.8 ± 23.5 500 ± -
LIF 30 4 0.78 ± 0.06 5.29 0.01 ± 0.001 1.02 ± 0.03 96.5 ± 36.8 500 ± -
DROPOUT
e
MEC 100 4 0.05 ± 0.01 2757.1
TIA 300 4 0.07 ± 0.02 3985.7
TOP 300 4 0.07 ± 0.01 3985.7
ZON 300 5 0.09 ± 0.01 3033.3
PRC 300 5 0.14 ± 0.03 2007.7
GAB 300 4 0.03 ± 0.02 14700
MCL 100 4 0.09 ± 0.02 1011.1
NIA 100 4 0.03 ± 0.02 3233.3
DPR 300 4 0.22 ± 0.1 354.55
Classification of Sodium Channel Inhibitors
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Due to limitations in time resolution of our protocol, we assigned a value of 3s for carbamazepine (CBZ) and lidocaine (LID) whose onset time constants were too short
to be resolved. On the other hand, lifarizine (LIF) and flunarizine (FLR) were completely irreversible within the duration of the protocol (200 s of washout); we assigned
the value 500 s as the offset time constant of these drugs.
Abbr.:
aconcentration,
binhibition (inhibited fraction) at 290 mV holding potential using the 5 Hz train protocol,
creversibility,
duse-dependence of the inhibition,
edrugs not potent enough for further investigation.
doi:10.1371/journal.pone.0015568.t002
Figure 1. Calculation of parameters and examples for the different types of inhibition caused by SCIs. A)–D) Peak amplitudes of evoked
currents (5 Hz trains of 5 depolarizations from 290 to 210 mV) are plotted against time. Black dots: Control. Grey dots: Drug perfusion. A)‘ Type 1’
inhibition (high potency, slow kinetics, partial reversibility, use-dependence). Calculation of properties of inhibition is illustrated. Inhibition: Inh =
(A12A3)/A1; IC50 =( 1 2Inh) * cc/Inh, where ‘‘cc’’ is the concentration; Reversibility: Rev =A 5/A1; Use-dependence: UD =( A 3/A4)/(A1/A2); ton and toff
are determined by monoexponential fitting of peak amplitudes of the first evoked current in each train. B) Use-dependent ‘Type 2’ inhibition (low
potency, fast kinetics, good reversibility, use-dependence). C) Non-use-dependent ‘Type 2’ inhibition (low potency, fast kinetics, good reversibility,
no use-dependence). D)‘ Type 3’ inhibition (high potency, very slow kinetics, apparently irreversible, no use-dependence). E) Calculation of Kr and Ki
values from steady-state availability curves.
doi:10.1371/journal.pone.0015568.g001
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Drug cc
a nI n h b ± SEM DV1/2 ± SEM Kr Ki2DV1/2 Ki2Kapp SD c Kr2Lit Ki2Lit
code mMm V mM mM mM mM mM
ANTIDEPRESSANTS
FLX 30 4 0.13 6 0.02 210.1 6 2.87 210.5 4.08 6.05 34.8 89.35 1.2
SRT 30 4 0.35 6 0.02 215 6 1.01 56.41 1.47 2.1 26.9 NDA ,1.7
PRX 30 5 0.55 6 0.09 211.4 6 3.77 24.19 1.99 0.73 33 17 1.45
AMI 10 3 0.08 6 0.03 211.3 6 2.47 133.9 1.45 3.34 40.1 38.11 0.52
30 3 0.20 6 0.02 211.2 6 0.76 124.9 3.69 4.92 25.4
100 3 0.59 6 0.05 218 6 1.89 69.62 1.65 2 34.8
IMI 30 4 0.25 6 0.08 29.37 6 2.89 107.2 3.82 5.98 17.9 26.46 0.89
DMI 30 4 0.35 6 0.04 25.87 6 0.53 57.03 8.06 4.37 13.1 29.24 1.15
MPR 10 4 0.12 6 0.03 24.11 6 0.88 89.66 5.63 3.17 28.3 18.33 1.45
NIS 100 4 0.34 6 0.02 26.68 6 0.52 194.2 19.1 7.1 27.3 NDA NDA
MIA 30 4 0.18 6 0.03 211.4 6 1.86 145.9 4.5 4.99 29.2 190 1.3
MRZ 100 4 0.24 6 0.01 212.8 6 0.20 316.8 5.63 7.62 41.6 NDA NDA
BPR 100 4 0.16 6 0.04 26.97 6 1.27 603.6 26 25.5 23.6 NDA NDA
VFX 100 5 0.11 6 0.02 24.66 6 1.11 888.7 59.5 63.4 14 8 0.64
NFZ 30 4 0.09 6 0.03 217.4 6 1.75 567.4 0.87 0.92 616 NDA NDA
TRZ 100 4 0.19 6 0.04 29.32 6 1.74 452 16.6 14.3 31.7 ,1000 ,111
ANTIPSYCHOTICS
HAL 30 5 0.22 6 0.03 24.72 6 1.24 113.5 13.8 2.96 38.4 7 0.28
CPM 30 7 0.32 6 0.05 218.4 6 0.69 69.64 0.29 0.82 85.4 3.18 0.19
CHX 30 4 0.20 6 0.05 215.8 6 2.18 128.5 0.73 1.74 74.1 NDA NDA
CLZ 100 4 0.29 6 0.02 28.35 6 1.42 248.6 11 12.4 20.1 NDA NDA
ANTICONVULSANTS
CBZ 300 4 0.21 6 0.02 211.4 6 0.19 1169 39.9 26.4 44.3 946.1 21.8
LTG 300 4 0.12 6 0.01 210.3 6 1.35 2267 31.3 36.7 61.8 1562 15.1
DPH 300 4 0.12 6 0.04 24.93 6 1.25 2536 208.2 70.8 18.4 701.1 16.2
LOCALANESTHETICS / ANTIARRHYTHMICS
BPV 100 6 0.14 6 0.01 211.3 6 0.79 618.9 5.85 7.79 79.5 291 20.1
LID 300 4 0.09 6 0.01 25.35 6 1.28 3192 89.6 65.7 48.6 686.7 17.7
MEX 300 4 0.32 6 0.03 210.3 6 1.82 638.2 26.8 17.9 35.8 395.1 12.4
FLC 300 8 0.82 6 0.01 212.4 6 0.94 64.69 7.9 5.7 11.3 354.9 5.55
MISCELLANEOUS
RAN 300 4 0.42 6 0.11 25.52 6 1.00 435.5 66.8 10.7 40.7 1000 75
MEM 100 6 0.29 6 0.02 21.77 6 0.54 242.2 109.8 28.5 8.5 178 6.67
RIL 30 3 0.08 6 0.01 215 6 0.47 373.6 2.17 3.43 108.8 62.4 0.49
100 3 0.22 6 0.01 229.2 6 0.42 359.5 0.48 1.63 219.5
DIC 100 4 0.03 6 0.01 23.73 6 1.00 3119 81 87.84 35.5 784.9 6.5
RIT 30 5 0.13 6 0.02 27.28 6 0.66 205.7 7.1 6.13 33.6 NDA NDA
AMB 100 4 0.33 6 0.01 29.87 6 0.90 200.9 12.2 17.6 11.4 110 8.17
SIL 100 4 0.43 6 0.03 27.66 6 0.86 132.8 14 6.7 19.8 340 34.9
TOL 100 4 0.21 6 0.02 26.47 6 1.74 391.1 30.9 21.1 18.6 384.3 5.07
FLR 10 5 0.04 6 0.00 29.59 6 1.33 241 2 1.75 137.4 NDA ,0.2
LIF 1 4 0.02 6 0.00 24.39 6 0.50 55.77 0.92 0.5 111.5 10.16 0.19
Measurements with different drug concentrations (e.g. amitryptiline and riluzole) resulted in similar Kr and Ki values, which confirmed the reliability of the calculations.
The table shows geometric mean of individual Kr,K i2DV1/2 and Ki2Kapp data (arithmetic mean 6 SEM values are shown in Results S7). Kr and Ki data from the literature
were calculated and averaged as described in [19]. Averaged data are shown in columns Kr2Lit and Ki2Lit, except for trazodone [42] and flunarizine [43].
Abbr.:
aconcentration,
binhibition (inhibited fraction) at holding potential 2150 mV,
cstate-dependence.
doi:10.1371/journal.pone.0015568.t003
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values were typically midway between Kr and Ki, while for many
‘Type 2’ and ‘Type 4’ drugs IC50 was closer to Kr (for further
discussion see Results S2).
In order to quantify differences and test the validity of the
subjective classification, we performed a cluster analysis using the
properties of inhibition. We took the logarithm of Kr,K i,I C 50,S D
and toff values, and normalized all seven properties by subtracting
the mean (of all drugs) from the values for individual drugs and
dividing by the standard deviation. Results of the cluster analysis
are shown in Figure 2B.
The overall picture represents the subjective description quite well.
‘Type1’ and ‘Type3’ inhibitions were clearly recognized, as well as the
separateness of riluzole and nefazodone. Using different amalgam-
ation rules and distance measures resulted in similar, although not
identical classifications. The differences between our subjective
classification and the result of cluster analysis were the following:
Flecainide, although had somewhat higher IC50, toff and Rev
values, was consistently clustered into ‘Type 1’ group. However,
despite the similar potency and kinetics, this compound has been
shown to have a separate mode of action, being an open channel
blocker [26].
‘Type 2’ and ‘Type 4’ groups were not clearly separated.
Bupivacaine was clustered into a separate subgroup of the
‘Type2’ – ‘Type4’ group together with mexiletine. However, its
UD and SD values (1.62 and 79.4, respectively) were higher than
the rest of either ‘Type 2’ or ‘Type 4’ compounds.
The biophysical properties of major groups are also shown in
Figure 3. The shape of each radar diagram gives an impression of the
actual type of inhibition. This way of illustration helps to judge the
correctness of our initial classification, and the classification by cluster
analysis.
Figure 2A also indicates that there was a strong correlation
between certain properties of inhibition. We calculated correlation
coefficients (for Kr,K i2Kapp,K i2DV1/2,I C 50, SD values and time
constants we used logarithmic transformation). All properties
significantly correlated with each other, with the exception of
UD and SD. Use-dependence only correlated with potency (Kr,
Figure 2. Localization of SCIs in the ‘‘biophysical space’’. Clustering based on properties of inhibition. A) Distribution of the biophysical
properties illustrated in a quasi-three-dimensional plot. Reversibility (Rev) values are plotted against Kr and Ki values, toff is color coded on a
logarithmic scale. Lack of use-dependence is indicated by underlined italic fonts. Drugs classified into different types of inhibition are circled. The
position of overlapping codes were minimally (,5%) adjusted for visibility. For exact values see Table 2 and Table 3. B) Result of a cluster analysis
based on seven properties of inhibition: log Kr, log Ki, log IC50, log SD, UD, Rev and log toff. (Weighted pair group average method was used as
amalgamation rule, with Euclidean distance measure.) L.D.: Linkage distance.
doi:10.1371/journal.pone.0015568.g002
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correlated with Rev and the two Ki values (Table 4), and notably
showed no correlation with Kr.
It is apparent that more potent drugs (whether potency was
measured by Kr,K i2 Kapp,K i2DV1/2 or IC50) tended to have
slower onset and offset kinetics, tended to be less reversible, and
tended to be more use-dependent. High inactivated state affinity
(low Ki) predicted high state-dependence, while high resting
affinity (low Kr) did not.
In summary, we have identified at least three distinct types of
inhibition, these may correspond with: i) different binding sites, ii)
different access pathways, iii) different modes of action (channel
block, stabilization of a non-conducting conformation, membrane-
mediated inhibition, deformation of the channel by an induced fit
mechanism, etc. - see [9]), iv) different binding kinetics (including
kinetics of: partitioning into and out of the membrane phase,
deprotonation and protonation, translocation between the two
leaflets of the membrane, horizontal diffusion within the
membrane and the actual entry to- and exit from the binding site).
The next logical question was, whether distincttypes of inhibition,
correspondwithspecificchemicalproperties,i.e.,whetherthetypeof
inhibition can be predicted based on chemical structure.
Figure 3. Properties of inhibition illustrated on radar diagrams. Different panels show different types of inhibition. ‘Type 2’ drugs were
divided into two panels (based on the results of cluster analysis) for the sake of visibility. For individual values of properties see Table 2 and Table 3.
doi:10.1371/journal.pone.0015568.g003
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biophysical properties of inhibition
We used the cheminformatics software JChem for Excel (see
Materials and Methods) to generate possible numerical chemical
descriptors (i.e., to calculate chemical properties from the chemical
structure). The correlation matrix of the 58 descriptors is given in
Results S3. The correlations helped to recognize informative
descriptors and to detect redundancies.
It was even more important to analyze correlations between
individual chemical descriptors and the eight properties of
inhibition, because this showed which specific chemical properties
affect individual aspects of inhibition. The complete analysis for all
58 descriptors is described in Results S4. Based on the correlations
among chemical descriptors (Results S3), and the correlations
between chemical descriptors and properties of inhibition (Results
S4 and S5), we selected the descriptors which were most
informative regarding the mode of action of SCIs (Results S4).
Only these descriptors will be discussed in the following section
(values for individual drugs are shown in Results S6).
T h es i n g l em o s ti m p o r t a n tc h e m i c a lp r o p e r t yt h a td e t e r m i n e d
potency(Ki,andIC 50) values,as well asreversibility ofdrugs,waslogP,
as seen in Figure 4A–B (R=20.53, 20.67, 20.74, and 20.76 for Kr,
Ki,l o g I C 50 and Rev, respectively) and in Results S4. The correlation
values of logD7.3 (the distribution coefficient at pH=7.3) were
considerably lower but still significant, except for Kr (R=20.06,
20.49, 20.38, and 20.54 for Kr,K i,l o g I C 50 and Rev, respectively),
which indicates that Kr was not influenced by logD7.3 (Figure 4D–E).
This suggests that the binding site and/or the access pathway is
separated from the extracellular environment, and in this local
milieu drug molecules are deprotonated. Lipophilicity of the
positively charged form seemed to be indifferent for the resting
binding site, but for the inactivated binding site it was important:
drugs which are strongly lipophilic even in their protonated form
were more potent against inactivated conformation.
Indeed, the property that showed the highest correlation with
logD7.3 was state-dependence (Results S4). This means that the
best predictor of high state-dependence for a drug was lipophilicity
of the dominant form of the molecule at pH=7.3, even though
this is the positively charged form for 27 out of the 35 molecules
(Figure 4F). Lipophilicity of the neutral form did not predict high
state-dependence (Figure 4C).
The next best predictor of state-dependence was aromaticity
(aromatic atom count, aromatic ring count, aromatic bond count).
These descriptors correlated significantly with SD, Ki and IC50
(R=0.54, 20.52, 20.49, respectively for aromatic atom count),
but not with Kr (R=20.21) (Figure 4G–I; Results S4). Measures
of aromaticity were also good predictors of reversibility and time
constants.
Table 4. Cross-correlation matrix for properties of inhibition (upper part) and correlations between properties of inhibition and
chemical descriptors (lower part).
log IC50 Rev
a log ton log toff UD
b log Kr log Ki2DV1/2 log Ki2Kapp log SD
c
log IC50 - 0.82 20.76 20.59 20.51 0.86 0.80 0.88 20.16
Rev
a 0.82 - 20.79 20.67 20.23 0.67 0.83 0.82 20.38
log ton 20.76 20.79 - 0.85 0.23 20.61 20.55 20.64 0.16
log toff 20.59 20.67 0.85 - 20.02 20.41 20.39 20.51 0.24
UD
b 20.51 20.23 0.23 20.02 - 20.49 20.34 20.38 20.11
log Kr 0.86 0.67 20.61 20.41 20.49 - 0.68 0.80 0.18
log Ki2DV1/2 0.80 0.83 20.55 20.39 20.34 0.68 - 0.92 20.48
log Ki2Kapp 0.88 0.82 20.64 20.51 20.38 0.80 0.92 - 20.44
log SD
c 20.16 20.38 0.16 0.24 20.11 0.18 20.48 20.44 -
MW
d 20.44 20.46 0.47 0.44 0.07 20.30 20.40 20.49 0.36
pKa
e 20.54 20.30 0.30 0.04 0.47 20.68 20.42 20.46 20.25
logP
f 20.74 20.76 0.60 0.58 0.14 20.53 20.73 20.67 0.32
PSA
g 0.39 0.24 20.25 20.11 20.35 0.39 0.26 0.24 0.19
logD7.3
h 20.38 20.54 0.36 0.48 20.19 20.06 20.54 20.49 0.69
Min.proj.area
i 20.55 20.49 0.55 0.43 0.33 20.37 20.41 20.50 0.27
Aromatic AC
J 20.49 20.63 0.61 0.58 20.08 20.21 20.48 20.52 0.54
log N(pKa)
k 0.41 0.23 20.22 20.00 20.45 0.64 0.24 0.18 0.55
p,0.05 p,0.01
Abbr.:
areversibility,
buse-dependence,
cstate-dependence,
dmolecular weight,
eacidic dissociation constant,
foctanol-water partition coefficient,
gpolar surface area,
hdistribution coefficient at pH=7.3,
iminimal projection area,
jaromatic atom count,
kN(pKa): the fraction of neutral molecules at pH=7.3.
doi:10.1371/journal.pone.0015568.t004
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PLoS ONE | www.plosone.org 11 December 2010 | Volume 5 | Issue 12 | e15568The most important determinant of Kr was pKa, the correlation
(R=20.68) was higher than with logP (R=20.53). Molecules
with high pKa values, i.e., which are predominantly positively
charged at physiological pH, were more potent against resting
channels, while inactivated affinity did not correlate with either
pKa or N(pKa). (Because the distribution of pKa values was rather
skewed, for the purpose of illustration, neutral fraction at pH=7.3
(designated as ‘N(pKa)’) was calculated from pKa values as
described in Materials and Methods. Because most drugs were
either neutral or positively charged at pH=7.3, N(pKa) is a good
substitute for pKa, with the only exceptions of phenytoin and
diclofenac, which have negatively charged forms (6.5% and
99.95%, respectively) at pH=7.3.) The correlations are shown in
Figure 4J–K. Interestingly, predominantly neutral molecules were
more state-dependent than positively charged ones (Figure 4L).
This is in contrast to the general view, that potent SCIs should be
predominantly positively charged molecules (see Introduction). On
the other hand, use-dependence was more prominent among
positively charged drugs (Figure 4M). Another descriptor that
showed significant (but only at p,0.05 level) correlation with both
Kr and UD (but not withKi), was polar surfacearea (PSA) (R=0.39
and 20.35, respectively). Small polar surface area corresponded
with higher resting affinity and higher use-dependence.
Timeconstants were determinedby aromaticity, lipophilicity and
the size of the molecule: large, lipophilic molecules with multiple
aromaticringshadsloweronset/offsetkinetics.Fromthedescriptors
which quantify different aspects of molecular size, minimum
projection area was found to show somewhat higher correlation
than molecular weight (Figure 4N–O). Larger molecules were also
found to be more potent (Figure 4P),which may partly be dueto the
fact that larger molecules are also more lipophilic.
In summary, we have identified chemical descriptors which
predict Kr,K i,I C 50, state-dependence, reversibility, use-depen-
dence, onset and offset time constants. While logP is essential for
both resting and inactivated state affinity, resting affinity is higher for
positively charged drugs, and interestingly, the lipophilicity of this
charged form does not seem to be important. One explanation may
be that this type of inhibition requires both interaction of the neutral
form with the membrane, and interaction of the charged form with
an aqueous environment. On the other hand, for inactivated state
affinity positive charge is not essential, in fact neutral molecules tend
to show higher state-dependence, furthermore lipophilicity of both
the neutral and the charged forms are important, as well as
aromaticity. This may suggest that the immediate environment of
the bound molecule is apolar, and binding probably involves p - p
interactions with aromatic residues (see discussion).
Classification of drugs based on chemical properties
We have investigated whether the type of inhibition can be
predicted from chemical properties of the molecule. We have
illustrated major chemical properties of the drugs in radar diagrams
(Figure 5). It is apparent from the figure, that ‘Type 1’, ‘Type 3’
groups, as well as the anticonvulsants of ‘Type 2’ form definite,
compact regions within the ‘‘chemical space’’, while the regions
which contain the rest of ‘Type 2’, and ‘Type 4 drugs are rather
indefinite, and contain compounds which are chemically diverse.
A cluster analysis of drugs based on 7 chemical descriptors
(molecular weight, minimum projection area, logP, logD7.3, log
N(pKa), polar surface area, and aromatic atom count) was
performed (Figure 6).
One of the three major groups contained ‘Type 3’ drugs
together with ritanserin and nefazodone, the second group all
‘Type 2’ drugs, and the third one contained all ‘Type 1’
compounds except ritanserin. ‘Type 4’ drugs, which produced
inhibition with properties between ‘Type 1’ and ‘Type 2’ were
classified together with either of these groups, and unclassified
drugs, as expected, were heterogenous, and were scattered among
the three major clusters.
The similarity between clustering based on biophysical or
chemical properties is obvious, which allows prediction of
biophysical properties with a considerable certainty. Within
certain sections of the ‘‘chemical space’’ (such as those populated
by ‘Type 1’, ‘Type 3’ compounds, or anticonvulsants from the
‘Type 2’ group; see Figure 5), specific inhibition types are
obviously predominant (may even be exclusive). Predominantly
positively charged (.98.75%; pKa 9.1 to 10.5) compounds with
two aromatic rings, high logP (3 to 5.2), MW between 260 and
330, and PSA less than 45 A ˚ 2 constituted the group of ‘Type 1’
drugs (without ritanserin). Anticonvulsant SCIs (a subset of ‘Type
2’ drugs), on the other hand, are predominantly neutral (.93.5%;
pKa,4.5), have relatively low logP (1.9 to 2.8), MW between 230
and 260, and PSA between 46 and 91 A ˚ 2. Finally ‘Type 3’ drugs
have three or four aromatic rings, a very high logP (5.8 to 6.2),
high MW (400 to 440), moderate pKa (7.5 to 8.2) and low PSA
(,37 A ˚ 2). It is yet to be verified experimentally whether other
compounds beyond the ones investigated in this study, which fall
within these sections of the ‘‘chemical space’’ are necessarily SCIs,
and whether they produce the expected type of inhibition.
Discussion
Classification of SCIs by automated patch clamp using
multiple properties of inhibition
SCIs are currently developed intensively for several indications,
such as pain syndromes, epilepsy, ischemia and neurodegenerative
diseases.
For drug development it is important to know the binding site as
thoroughly as possible. It is often assumed that sodium channels
possess a single drug binding site (the ‘‘local anesthetic receptor’’),
however, several experimental data indicate that alternative
binding sites and alternative modes of action do exist. From the
35 drugs investigated in this study 10 has been studied on mutant
channels. Lidocaine, mexiletine and ranolazine seem to share the
binding site; for amitriptyline, lamotrigine, phenytoin, flecainide
and bupivacaine the binding site seem to partially overlap with the
local anesthetic binding site; and for sertraline and paroxetine an
entirely different binding site seems to exist [9]. Although a
comparative study of a number of SCIs on mutant channels would
be a much needed endeavor, in this study we did not directly study
possible binding sites by mutagenesis. Instead we attempted to
perform a classification of SCIs using wild type channels. This
approach is unable to prove alternative binding sites, but it is able
to pinpoint drugs or groups of drugs with specific modes of action,
which are worth studying with other approaches. We believe that
the results of this classification will give directions to later studies of
different binding sites.
Figure 4. Dependence of properties of inhibition on specific chemical properties. Drugs belonging to different types of inhibition are
shown in different colors. For values of individual drugs see Table 2, Table 3 and Results S6. Biophysical properties plotted against chemical
descriptors. A)–C): logP, D)–F): logD7.3, G)–I): aromatic atom count, J)–M): logN(pKa), N)–P): minimal projection area. Regression lines and correlation
coefficients (R) are only shown where the correlation was significant (p,0.01).
doi:10.1371/journal.pone.0015568.g004
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PLoS ONE | www.plosone.org 12 December 2010 | Volume 5 | Issue 12 | e15568We found that SCIs are diverse in their potency, kinetics,
reversibility, use-dependence and state-dependence. We described
three major types of inhibition, and besides we identified a number
of compounds (e.g., nefazodone, riluzole, flecainide) which have
additional distinct modes of action.
Prediction of properties of inhibition using chemical
descriptors
We identified specific chemical descriptors which predict
particular properties of inhibition.
Partition coefficient (logP) was a major determinant of potency,
kinetics and reversibility. Lipophilic molecules tended to be more
potent in terms of Kr,K i and IC50 (measured at -90 mV, using the
5 Hz train protocol) values; in addition the inhibition was less
reversible, with slower onset and offset kinetics. This is in
accordance with studies on structure-activity relationships, where
a linear relationship between logP and logIC50 values were
described based on the inhibition of action potentials [17,27] and
of [
3H]BTX binding [15,16,18]. A similar relationship between
lipophilicity and potency has been shown for a number of other
transmembrane proteins [28,29,30].
Figure 5. Selected chemical descriptors of drugs illustrated on radar diagrams. Different panels show different types of inhibition. ‘Type 2’
drugs were divided into two panels as in Figure 3, for the sake of visibility. For individual values of properties see Results S6.
doi:10.1371/journal.pone.0015568.g005
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be either of the following two possibilities: (1) SCIs must cross the
membrane in order to enter a hydrophilic environment (which
may be the intracellular fluid or the binding site itself); therefore, in
order to be able to cross the membrane, the drugs must be
lipophilic. (2) The binding site itself is hydrophobic. The first
explanation supposes that drug molecules have to partition into
the membrane, and then out of the membrane toward the
intracellular fluid or the binding site. Too high lipophilicity would
prevent effective partitioning out of the membrane environment;
therefore logP should have a definite optimum. Although it cannot
be statistically proven from our data, note that in Figure 2A the
mean of Kr values (left panel) for ‘Type 1’ drugs is smaller than the
mean Kr of the more lipophilic ‘Type 3’ drugs, while for Ki values
(right panel), more lipophilic ‘Type 3’ drugs are more potent than
the average of ‘Type 1’ drugs. This may suggest that lipophilic
interactions (logP and logD) are more important in inactivated
state affinity.
Among the eight properties of inhibition state-dependence (i.e.,
Kr/Ki ratio) is of particular importance. It is thought to be
essential for the safety of SCIs: state-dependent drugs are able to
selectively inhibit excessive/pathological firing patterns, such as in
epilepsy, neuropathic pain or cardiac arrhythmia, while their effect
on normal firing activity is minimal.
Distribution coefficient at pH=7.3 (logD7.3) was the best
predictor of state-dependence, and one of the best predictors of
Ki. Drugs with high logD7.3 were more state-dependent, and had
high inactivated affinity, while this property was irrelevant for
resting affinity (see Figure 4D and E). There are two major reasons
why logD7.3 of a drug can be high: Some of the compounds had a
logP so high (.4.0), that even in their charged form they were still
strongly lipophilic (some examples are fluoxetine, sertraline,
amitriptyline, imipramine, haloperidol, chlorpromazine, chlor-
prothixene and silperisone). Some other compounds had a low
pKa value (,8.2), which means that a considerable fraction
(.10%) of the molecules is neutral at pH=7.3, therefore there is
not much difference between logP and logD7.3 (less than 1 unit).
Some examples are carbamazepine, lamotrigine, phenytoin,
mirtazapine, trazodone, bupivacaine and ranolazine. Finally,
there were five drugs, where both the logP was high and the
pKa was low: nefazodone, riluzole, ritanserin, flunarizine and
lifarizine. These drugs (with the exception of ritanserin) had the
highest state dependence values among the 35 drugs investigated.
From this reasoning it follows, that the ratio of neutral form,
N(pKa) also had to be a major determinant of state-dependence.
Indeed, less charged molecules were found to be more state-
dependent. This is contrary to the widely held view that SCIs
should be positively charged. Because there was no significant
correlation between N(pKa) and logD7.3 (neutral molecules did not
have higher logD7.3 values), the ratio of neutral molecules
probably affects state-dependence directly.
On the other hand, if we consider resting affinity, we can notice
that positively charged SCIs tended to be more potent. The
finding, that positively charged molecules are better inhibitors of
resting channels irrespectively of the lipophilicity of the charged
form (Kr did not depend on logD7.3), suggests that in resting
inhibition an interaction of the charged form and the channel
occurs within a polar environment. The major determinant of
resting affinity was found to be pKa, indicating the importance of
positive charge in resting inhibition. It was also the most important
determinant of use-dependence, which is in accordance with
previous studies, where positively charged molecules had slower
kinetics and showed more use-dependence [4,17,20,21,31,32].
The third major determinant of state-dependence is aromatic-
ity. While resting affinity was not dependent on the number of
aromatic rings, inactivated affinity showed a definite dependence.
This suggests that interactions between aromatic rings (p-p
interactions) are important in binding to inactivated state.
Aromaticity also determined time constants and reversibility. This
may be one explanation of the finding that dimers of lidocaine
(containing two aromatic rings) show both increased potency and
decreased reversibility [33].
Figure 6. Clustering based on selected chemical descriptors. Result of a cluster analysis based on seven chemical descriptors: logP, logD7.3,
MW, polar surface area, aromatic atom count, minimal projection area and log N(pKa). (Ward’s method was used as amalgamation rule, with
Euclidean distance measure.) L.D.: Linkage distance.
doi:10.1371/journal.pone.0015568.g006
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local anesthetic binding site (Phe1710 in rNav1.3) in use-
dependent- but not resting inhibition has been shown by different
amino acid substitutions. For resting inhibition hydrophobicity of
the residue was sufficient, while effective use-dependent inhibition
required that the residue was aromatic [34]. The role of the
aromatic ring has also been investigated by using unnatural
derivatives of phenylalanine (Phe1579 in rNav1.4) in which the p
electron clouds were distorted. This affected use-dependent
inhibition, and recovery from inactivated state, but left tonic
inhibition (resting affinity) intact [10]. These results could be
explained by either cation-p or p-p interactions. Our results
support the role of p-p interaction, which is consistent with single
channel analysis of the inhibition by local anesthetics; two distinct
types of inhibition were observed at single channel level: rapid
block (manifested as decreased single-channel conductance), and
discrete block (appearance of distinct closed periods). The former
could be reproduced by the charged amine fraction of local
anesthetics, while phenol, which resembles the aromatic part of
local anesthetics, caused discrete block [35]. Mutation of the
phenylalanine residue (Phe1579 in rNav1.4) abolished discrete
block, while not affecting rapid block [12].
In summary, we propose that drugs with high state-dependence
are more likely to be found among compounds which contain
more than one aromatic rings, and which have logD7.3 .3.0, and
pKa ,8.0 (conformity with all three conditions is not absolutely
necessary). We have identified a couple of highly state-dependent
compounds, which could be used as a basis for further drug
development. The SCI property of bupivacaine, riluzole, flunar-
izine and lifarizine are well known, but we would like to call
attention to the attractive properties of nefazodone, chlorproma-
zine and chlorprothixene, as highly state-dependent SCIs.
Our data confirm our previous results based on a meta-analysis
of the literature [19]. We attempted to find chemical properties
which predict resting and inactivated affinity. The advantage of
that study was the larger pool of data (139 compounds), which
theoretically should help identification of correlations. However,
the diversity of preparations, experimental protocols and analysis
methods seriously compromised comparability. We could detect
the role of logD7.3, and aromaticity in determining Ki, but the
correlations were less convincing. Furthermore, the role of positive
charge in resting affinity, and neutrality in inactivated affinity
could not be detected. The advantages of using identical
experimental conditions for all drugs – as in our current study –
are: improved reliability of data, the possibility of correlating
chemical properties with multiple biophysical properties, and the
possibility of detecting distinct types of inhibition within the
‘‘multi-dimensional space’’ defined by both biophysical properties
of inhibition and chemical properties of the molecules.
What is the significance of identification of different
types of inhibition?
Therapeutic applicability is not determined solely by the potency.
In fact some of the most widely used drugs (lidocaine, phenytoin,
carbamazepine) are among the least potent SCIs. However, we
expect that SCIs acting by similar mechanisms will have similar
therapeutic action (provided that sodium channel inhibition is the
principal element in its effect). In this respect it is important to find
out about different types of inhibition, to locate novel drugs in the
‘‘biophysical space’’, and to learn how this location is determined by
chemical properties. This study, of course, have not accomplished
mappingofthe entire ‘‘biophysical space’’ for SCIs, butwe hope the
concept has been introduced, and at least we have identified three
basic types of inhibition and a couple of additional drugs with
interesting properties. Antiarrhythmics and local anesthetics
(bupivacaine, lidocaine, mexiletine and flecainide) were a diverse
group, while the three anticonvulsants (carbamazepine, phenytoin,
lamotrigine) were found to be similar. A group of antidepressants:
selective serotonin reuptake inhibitors, tricyclic antidepressants and
maprotiline formeda fairlyhomogenousgroup,whilethe remaining
antidepressants were diverse in both chemical and biophysical
properties. It is worth noting that flunarizine and lifarizine
(neuroprotective agents [36]) occupy a specific area in both
‘‘biophysical space’’ and ‘‘chemical space’’.
Summary and conclusions
In summary, we have recorded multiple parameters of
inhibition, which did not make our measurement more costly or
time consuming but provided us with additional information. With
this extra information, we established that SCIs are heterogeneous,
delineated specific types of inhibition, and with the help of
chemical descriptors identified specific predictors of state-depen-
dence. The protocols used in this study were fairly simple; the
accuracy of the method can be further improved by including
measurements for additional biophysical parameters (e.g. frequen-
cy-dependence, pH-dependence, etc). The challenge is to
maximize the information content that can be obtained from
more complex protocols, while not increasing the cost of
measurements, and keeping the analysis manageable.
We believe that this new approach of mapping drugs in the
‘‘biophysical space’’, rather than determining a single IC50 value
will help drug discovery, especially if we can determine the specific
chemical properties which predict individual types of inhibition.
This concept may be particularly profitable in the study of certain
ion channels, which are notorious of their promiscuity in drug
binding.
Materials and Methods
Cell cultures
HEK-293 cells stably expressing rNav1.2 sodium channels were
obtained from NeuroSearch (Ballerup, Denmark). The cells were
grown in Dulbecco’s modified Eagle medium (catalog no. 32430-
027, Invitrogen) supplemented with 10% FBS. Prior to use, the
cells were trypsinized (catalog no. 15400-054, Invitrogen) and
subsequently kept in suspension in the QPatch cell storage facility
in CHO-S- SFM-II medium (catalog no. 12052-114, Invitrogen).
Solutions and drugs
Cells were automatically prepared for application to the chips
(centrifuged and washed twice, then resuspended in extracellular
solution) as described previously [37]. Composition of the
extracellular solution was: (in mM): 140 NaCl, 3 KCl, 1 CaCl2,
1 MgCl2, 0.1 CdCl2, 20 TEA-Cl, 5 HEPES, adjusted to pH 7.3,
Osmolality: ,320 mOsm. The intracellular solution consisted of
the following (in mM): 135 CsF, 10 NaCl, 1 EGTA, 10 HEPES,
adjusted to pH 7.3 with CsOH (,5 mM), Osmolality:
,320 mOsm.
Drugs were obtained from Sigma, Tocris, or synthesized in
GedeonRichterPlc.(Budapest,Hungary).Thelist ofdrugstogether
with the three-letter codes, as well as their therapeutic indication,
main mechanism of action, and human plasma concentration are
shown in Table 1. Source of drugs and preparation of stock
solutions are shown in Materials and Methods S1.
Electrophysiology
All electrophysiological experiments were conducted on
Qpatch-16 or QPatch HT instruments using QPlate
TM chips.
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chips see [37,38]. Data were sampled at a frequency of 25 kHz
and filtered at 5 kHz. Junction potential was calculated to be
211 mV and was corrected for. The amplifier was controlled and
the data were collected by the Sophion QPatch client software.
For initial data analysis the QPatch software was used. Built-in
amplifiers provide an improved method for series resistance
compensation. Leak subtraction (based on a standard P/n
protocol) was used to subtract the capacitive component of
currents.
Chip properties, distribution of gigaseal properties and stability
of whole-cell parameters were essentially the same as described
before for HEK-293 cells [37,39]. Distribution of whole-cell
membrane resistance, series resistance, whole-cell capacitance
values and current amplitudes, as well as voltage-conductance
curves for activation and inactivation with V1/2 values and slope
factors are shown in Materials and Methods S2.
Analysis of data from the 5 Hz train protocol. From this
protocol we extracted five parameters, as illustrated in Figure 1A.
We calculated inhibition of a single ‘‘cc’’ concentration: Inh =
(amplitudectr – amplitudedrug)/amplitudectr.I C 50 values were estimated
using the rearranged Hill equation assuming one-to-one binding:
IC50 =( 1 2Inh) * cc/Inh. Reliability of the calculation was verified
by measuring the effect of different concentrations of the same
drug (in the case of 5 out of the 35 drugs). The process is illustrated
using the example of lidocaine in Materials and Methods S3.
Analysis of data from the steady-state inactivation
protocol. Resting affinity (Kr) values were calculated from the
inhibition at 2150 mV pre-pulse potential (Inh2150), using the
rearranged Hill equation as described above (Figure 1E).
Inactivated affinity (Ki) values were calculated assuming a simple
four-state model of drug binding and channel gating [40], using two
separate methods: (1) from the shift of the availability curve (DV1/2),
the slope of the Boltzmann fit of the availability curve (k) and Kr,
using the formula described by Bean, Cohen and Tsien [40]
(Ki2DV1/2; see Figure 1E), or (2) from the apparent affinity (Kapp)a t
a certain pre-pulse potential, which was calculated from the
inhibition (e.g. Inh260) as described above, and the availability (h)
at the same pre-pulse potential, using the formula from Kuo and
Bean [41] (Figure 1E). Differences between the two calculations of
Ki were minimal, Ki2DV1/2/Ki2Kapp ratios were 0.9860.098. For
further analysis Ki values obtained with the latter method were
used,because theseseemed more reliable(and theycouldbe verified
at different holding potentials). Geometric means of measured Kr,
Ki2DV1/2 and Ki2Kapp values are shown in Table 3. (Arithmetic
means and SEM values are given in Results S7.)
Cheminformatics
Chemical descriptors were generated using JChem for Excel
1.1.1 and Marvin 5.2 software from ChemAxon (Budapest,
Hungary). Neutral fraction of drugs at pH=7.3 was calculated
using the rearranged Henderson-Hasselbalch equation:
N(pKa)=10
pH/(10
pH+10
pKa).
Data analysis and statistics
Exponential fitting was made using Origin 8 (Originlab,
Northampton, MA). Statistical analysis was performed using
Statistica 8.0 (StatSoft, Inc., Tulsa OK).
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